RadNet, Inc. (RDNT) Stock Price & How to Invest

RadNet operates a network of several hundred outpatient imaging centers, mostly clustered in dense markets such as California, the Northeast, Maryland and Florida, and many of them are run in joint venture with local hospitals and health systems. The centers perform MRI, CT, PET, mammography, ultrasound and X-ray, and revenue comes primarily from commercial insurers, Medicare and Medicaid, plus a growing slice of self-pay screening. A second reporting segment, Digital Health, houses DeepHealth, the company's radiology AI and software business, which sells clinical AI tools, imaging workflow software and an enhanced breast cancer detection add-on that patients often pay for directly. The 2026 acquisition of Gleamer widened that segment's product range and installed base internationally.

The investment picture is a capital-intensive services business trying to become part software company. Scale matters in imaging because scanners are expensive, utilization drives margin, and payers negotiate rates network by network, which is why RadNet keeps buying and building centers in markets where it is already dense. Growth has been real: first quarter 2026 revenue was roughly $575.6M, up about 22% year over year, and management guided 2026 revenue growth of roughly 17% to 19% with adjusted EBITDA growth of roughly 18% to 22%. The complication is that GAAP profitability is thin to negative once depreciation, interest and stock compensation are counted, and the balance sheet carries close to $1.93B of debt. The market has been paying roughly $5.0B of equity value for that combination, which prices in the Digital Health segment scaling rather than staying a rounding error.

Reimbursement is set largely by Medicare and by commercial contracts, so a rate cut or an unfavorable contract renewal flows almost straight to operating income. The business is capital intensive: scanners, buildings and IT require ongoing spending, and roughly $1.93B of debt against roughly $455M of cash means interest expense is a permanent line item and refinancing conditions matter. Trailing twelve month net income has been slightly negative, so valuation rests on adjusted EBITDA, free cash flow and the Digital Health growth story rather than on reported earnings. Radiologist supply is tight and labor cost inflation has been a persistent pressure across the industry. Finally, the AI segment faces credible competition from imaging equipment makers and well-funded startups, and if it stays a small share of revenue the company gets valued like the capital-heavy services business it mostly still is.

8 analysts publish price targets on RDNT, averaging $89.75 against a $72.39 price as of August 2026, or +24.0%. The published targets run from $65.00 to $100.00, a moderate spread, and the ratings split 8 buy, 0 hold, 0 sell. Over the last six months there have been 0 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RDNT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on RadNet, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The site-of-care shift out of hospitals. A hospital outpatient department typically bills far more for the same MRI or CT than a freestanding center does, so insurers and employers have steadily steered volume toward independent imaging. The most optimistic published target, $100.00, assumes this works close to its best case.

The case against. Reimbursement is set largely by Medicare and by commercial contracts, so a rate cut or an unfavorable contract renewal flows almost straight to operating income. The most pessimistic target, $65.00, is roughly what RDNT is worth if this bites instead.

Read the full bull and bear case on RDNT, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see RadNet, Inc.'s investor relations page or your broker.

• Market cap: ~$5.0B (late July 2026)
• Revenue (TTM): ~$1.9B
• Q1 2026 revenue: ~$575.6M, up ~22% year over year
• Q1 2026 adjusted EBITDA: ~$63.3M
• Net income (TTM): ~negative $18.7M (GAAP)
• Total debt / cash: ~$1.93B debt against ~$455M cash

At roughly $5.0B of market value on roughly $1.9B of trailing revenue, RDNT trades near 2.6 times sales for a business whose GAAP bottom line is around breakeven, so the multiple is being carried by adjusted EBITDA, free cash flow growth and the Digital Health segment rather than by earnings. Management's 2026 guidance calls for revenue growth of roughly 17% to 19% and adjusted EBITDA growth of roughly 18% to 22%, which is the frame most of the sell side uses. Second quarter 2026 results were scheduled for August 10, 2026, so the figures above reflect Q1 2026 and the most recent trailing data available before that report.

Other names that sit close to RDNT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get RDNT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so RDNT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RDNT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

RadNet is a scale imaging operator with a software business bolted on, so the stock tends to follow scan volumes, reimbursement rates and how quickly the AI segment compounds.

Whether RDNT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RDNT a buy or a sell?, and where the stock could go from here in the RDNT stock forecast.

For income investors, whether RDNT pays a dividend and how the payout looks is covered in does RDNT pay a dividend? And to weigh RDNT against a peer, read the full side-by-side comparisons: RDNT vs GEHC and RDNT vs HNGE.